News Search

Category: Schools

Four Penn Medicine Studies Named Among Nation’s Top 10 Clinical Research Advances 

The Clinical Research Forum’s Top 10 Clinical Research Achievement Awards honor outstanding accomplishments in clinical research.

CarboWells Wins the 2026 Y-Prize Competition

The winning idea is based on technology developed by Shu Yang, PhD.

Penn Medicine and CHOP Faculty Make the TIME100 Health List for CRISPR Gene Therapy Breakthrough 

Two doctors were recognized by TIME as pioneers in healthcare for successfully treating KJ Muldoon.

Penn Received $7.8 Million from ARPA-H to Advance Lymphatic Imaging and AI-Driven Disease Detection  

The project is led by Maxim Itkin, MD, Professor of Radiology at Penn Medicine and the director of Penn’s Center for Lymphatic Disorders.

T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases   

By targeting disease-specific proteins, this antigen-specific immunotherapy aims to selectively eliminate damaged cells, potentially offering a more precise and effective treatment approach. 

Penn Expands its Immunology Research  

Penn’s newly developed seven-story facility at 3600 Civic Center Boulevard will bring together labs across disciplines to advance breakthroughs in immune health, autoimmunity, and infectious diseases.

Dispatch Bio Developing Tumor-Agnostic Immunotherapy Targeting Solid Tumors  

The technology, now in preclinical development, has the potential to overcome the limitations of traditional cancer treatments for solid tumors.

Opus Genetics Reports Positive Pediatric Data from its Clinical Trial Evaluating Investigational Gene Therapy for a Rare Eye Disorder  

These findings suggest OPGx-LCA5, Opus Genetics' investigational gene augmentation therapy, could improve vision for patients previously considered untreatable.

GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment 

Its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA.

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel 

Rese-cel is an experimental CAR T-cell therapy designed to “reset” the immune system in people with autoimmune diseases.

Filter

Skip to content